Prospective Lifespan Cohort of Myocardial Infarction
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Acute Myocardial Infarction (AMI), Stable Angina, Unstable Angina. Basic parameters: 18 years — 74 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Prospective Lifespan Cohort Study of Myocardial Infarction for Building an Integrated Multidimensional Database and Developing an Artificial Intelligence- and Multi-omics-Driven Precision Prevention and Control System
Overview
This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management. The study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up. The primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.
Primary outcome measures
- Rate of all-cause mortality [Time frame: From enrollment to the end of study follow-up, up to 5 years]
Secondary outcome measures (7)
- Rate of cardiovascular death [Time frame: From enrollment to the end of study follow-up, up to 5 years]
- Rate of recurrent myocardial infarction [Time frame: From enrollment to the end of study follow-up, up to 5 years]
- Rate of readmission due to heart failure [Time frame: From enrollment to the end of study follow-up, up to 5 years]
- Rate of target vessel or non-target vessel revascularization [Time frame: From enrollment to the end of study follow-up, up to 5 years]
- Rate of stroke [Time frame: From enrollment to the end of study follow-up, up to 5 years]
- Rate of definite or probable stent thrombosis [Time frame: From enrollment to the end of study follow-up, up to 5 years]
- Rate of severe bleeding [Time frame: From enrollment to the end of study follow-up, up to 5 years]
Eligibility criteria
Inclusion criteria
Age 18 to 74 years
Diagnosed with stable angina, unstable angina, or acute myocardial infarction
For acute myocardial infarction: symptom onset to hospital admission less than 24 hours, with patients undergoing emergency percutaneous coronary intervention prioritized
Diagnosis of acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction
Willing to participate and able to provide written informed consent
Able to complete baseline assessment, biospecimen collection, and long-term follow-up
Exclusion criteria
End-stage malignant tumor with expected survival of less than 1 year
Severe hepatic or renal dysfunction (estimated glomerular filtration rate <30 mL/min/1.73 m² or Child-Pugh class C)
Active autoimmune disease or long-term use of immunosuppressive agents
Pregnant or breastfeeding women
Inability to provide informed consent or severe cognitive impairment
Previous participation in another clinical study that may conflict with this project
Any other condition considered by the investigators to make participation inappropriate
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Fuzhou University Affiliated Provincial Hospital — Fuzhou
Identifiers
NCT: NCT07471763 · K2026-03-001